Counter Grandma portions
Counter Grandma treats
Bayer logo Bayer logo Bayer logo Bayer logo
Xarelto logo
DOSING GUIDE
PRACTICAL MANAGEMENT
PRESCRIBING INFORMATION

Consistent Protection after Knee Replacement Surgery, Evidenced in Clinical Studies,1,2 Reaffirmed in the Real-World3

Prevention of VTE after elective knee replacement surgery

The first approved indication4 for Xarelto® was for the prevention of venous thromboembolism in adults undergoing elective knee replacement surgery

Superior Protection for Your Elective Knee Surgery Patients1

Provide better protection against DVT , nonfatal PE and death from any cause vs enoxaparin

Xarelto significantly reduces DVT (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal PE , or death from any cause by 9.2% ARR vs enoxaparin.1

RECORD 3 efficacy

Comparable Safety Profile1

Maintain a low major bleeding rate vs enoxaparin

Treatment with Xarelto results in a similar major bleeding rate as enoxaparin in elective knee replacement surgery patients.1

RECORD 3 efficacy

Effective Thromboprophylaxis Achieved with Less Medicinal Treatment2

Better protect your patients with less medicinal treatment vs enoxaparin

Treatment with Xarelto 10 mg OD for 10–14 days significantly reduces DVT (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal PE , or death from any cause up to day 17 after surgery by 3.2% ARR vs enoxaparin 30 mg BID.2

RECORD 4 efficacy

Consistent Protection Confirmed in the Real World3

Give your everyday patients the consistent protection they need

Xarelto has been associated with significantly lower symptomatic thromboembolic events vs standard of care (0.9% vs 1.4% [OR, 0.65; 95% CI, 0.49–0.87]) in elective hip and knee surgery patients.3

xamos

* Standard of care included, but was not limited to, LMWHs, unfractionated heparins, fondaparinux, dabigatran etexilate, acetylsalicylic acid and vitamin K antagonists.

Major bleeding rates were similar in patients treated with either Xarelto or standard of care.3

XAMOS safety

* Standard of care included, but was not limited to, LMWHs, unfractionated heparins, fondaparinux, dabigatran etexilate, acetylsalicylic acid and vitamin K antagonists. † As defined in the RECORD studies clinically overt bleeding that was fatal, occurred in a critical organ, necessitated re-operation or was outside of the surgical site and was associated with a fall in haemoglobin of ≥2 g/dl or required a transfusion of ≥2 units of blood.

ARR, absolute risk reduction; CI, confidence interval; DVT , deep vein  thrombosis ;  ITT , intention-to-treat;  LMWH , low-molecular-weight heparin; OD, once daily; OR, odds ratio;  PE , pulmonary embolism; RRR , relative risk reduction; VTE , venous thromboembolism.

 

PP-XAR-ALL-1794-1

References

RELATED PODCAST
CAD or symptomatic PAD discussion

 

 

RELATED VIDEOS
Coronary Artery Disease Causes and Consequences

Atrial Fibrillation Explained

Atrial Fibrillation Explained
Atrial Fibrillation Explained

Cancer-Associated Thrombosis Minimizing the Burden of Injection for Patients wit

Cancer-Associated Thrombosis: Minimizing the Burden of Injection for Patients with CAT
Cancer Associated Thrombosis or CAT treatment without the burden of injection; Your patients with cancer-associated thrombosis need an effective VTE treatment; Find out how to minimise the burden of anticoagulant treatment for patients with cancer-associated thrombosis

Why a Blood Clot is Serious

Why a Blood Clot is Serious
Coronary Artery Disease Causes and Consequences Coronary Artery Disease Causes and Consequences

Fibrillation Explained
Cancer-Associated Thrombosis Minimizing the Burden of Injection for Patients wit
Why a Blood Clot is Serious

© 2020 Bayer AG

This website contains information on Xarelto (rivaroxaban) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK.

Last updated on 05/02/2020